



(51) International Patent Classification:

A61K 31/52 (2006.01) A61K 31/69 (2006.01)
A61K 31/4035 (2006.01) A61K 38/07 (2006.01)
A61K 31/496 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2025/010087

(22) International Filing Date:

02 January 2025 (02.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/616,928 02 January 2024 (02.01.2024) US
63/727,941 04 December 2024 (04.12.2024) US

(71) Applicant: **K36 THERAPEUTICS, INC.** [US/US]; 1 Main Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **CONNOLLY, Terrence Joseph**; c/o K36 Therapeutics, Inc., 1 Main Street, Cambridge, Massachusetts 02142 (US). **QUIGLEY, Michael Travis**; c/o K36 Therapeutics, Inc., 1 Main Street, Cambridge, Massachusetts 02142 (US). **WINOGRAD, Benjamin**; c/o K36 Therapeutics, Inc., 1 Main Street, Cambridge, Massachusetts


02142 (US). **XU, Lan**; c/o K36 Therapeutics, Inc., 1 Main Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **ARICO, Joseph W.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: PIPERIDINYL-METHYL-PURINEAMINE NSD2 INHIBITOR THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER



(57) Abstract: The present invention provides methods and compositions for using a piperidinyl-methyl-purineamine nuclear SET domain-containing protein 2 (NSD2) inhibitor to treat cancer, such as combination therapies to treat cancer.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*